Some people respond better than others, and some may need a different type of support depending on their symptoms or side effects
Looking ahead, "next-gen" challengers like Amgen (NASDAQ: AMGN) and Viking Therapeutics (NASDAQ: VKTX) are positioned as potential winners if they can offer better dosing convenience
Hair loss from GLP-1 is temporary telogen effluvium caused by rapid weight loss and metabolic stress, not medication toxicity
Developed by Eli Lilly, its molecular structure incorporates modified amino acids and a fatty acid side chain designed to extend its duration of action
Relevance within studies on glucose regulation and insulin sensitivity
This article breaks down where the retatrutide trials stand, what the timeline to approval actually looks like, how it compares to drugs you can already access, and what your options are today if you don't want to wait two years